Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

Generated $78.3 million in net product sales of XDEMVY®, an increase of 217$135 million raised in public equity offering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to h ...